https://jcbior.com/index.php/JCBioR/issue/feed
Journal of Current Biomedical Reports
2023-12-17T15:56:50-05:00
Prof. Seyed Asghar Havaei
admin@jcbior.com
Open Journal Systems
<p>Journal of Current Biomedical Reports (J Curr Biomed Rep) is an open access, peer-reviewed journal which accepts different types of papers in all aspects of basic medical sciences to facilitate and enhance the global exchange of knowledge. The Editorial Board consists of outstanding specialists in biomedical research that guarantee accuracy and quality of peer-review process for submitted manuscripts. We are eager to receiving submissions from all over the world particularly high-quality papers presenting advances in their own research fields. The general fields of interest are...</p><p><a title="FOCUS AND SCOPE" href="/index.php/JCBioR/about/editorialPolicies#focusAndScope" target="_blank">Read more</a></p>
https://jcbior.com/index.php/JCBioR/article/view/216
Mycological profile of fungi associated with rhino-orbital mycosis in post-COVID-19 patients
2023-12-17T03:16:20-05:00
Swati Mudshingkar
drswati2006@gmail.com
Sachin Deorukhkar1
drswati2006@gmail.com
Jaishree Petkar
drswati2006@gmail.com
Chetana Joshi
drswati2006@gmail.com
<div><p>Rhino-orbital mycosis is devastating fungal infection with high mortality and morbidity despite of recent advances in its diagnosis and treatment. It is caused by filamentous fungi of Mucorales order of the class of Zygomycetes. Rising number of cases presenting with fungal rhino-sinusitis with or without orbital involvement in patients recovered from coronavirus disease 2019 (COVID-19) infection was observed. Hence, present study was undertaken at a tertiary care hospital to know the mycological profile of fungi associated with these infections. Various clinical samples like deep nasal swabs, tissue from nasal cavity, nasal sinuses and orbital cavity were processed to isolate and identify fungi from suspected mucormycosis patients with standard mycological processes. Total 480 specimens from 226 patients suspected of mucormycosis were received in microbiology department of a tertiary care hospital, over 3 months period from April to June 2021. Rhino-orbital mycosis predominantly affected males and population over 50 years of age. Overall KOH positivity rate was 22.2% and culture positivity rate was 27.7% which was highest for tissue samples followed by deep nasal swabs. Most common isolate was <em>Rhizopus</em> spp. (51%) followed by <em>Mucor</em> (22%), <em>Aspergillus</em> (13%) and <em>Rhizomucor</em> (5%). Mixed infections with <em>Mucor</em> and <em>Aspergillus</em> were seen in 4% patients. Mucormycosis was observed in majority of post-COVID-19 patients and patients with high blood sugar. The majority of patients (64.1%) were suspected to have nasal involvement. Early diagnosis and prompt treatment play pivotal role in cases of mucormycosis. One should be vigilant to diagnose rhino-orbital mycosis as it is dreaded complication.</p></div>
2023-09-29T00:00:00-04:00
Copyright (c) 2023 © The Author(s)
https://jcbior.com/index.php/JCBioR/article/view/234
Effect of empagliflozin on liver function in type 2 diabetes: A systematic review and meta-analysis of randomized trials
2023-12-17T15:56:50-05:00
Zahra Rafat
rafat.zahra2015@gmail.com
Kourosh Delpasand
kd388@yahoo.com
Davoud Roostaei
droostaei@gmail.com
<div><p>Many reports are indicating the blood sugar-lowering potential of empagliflozin in type 2 diabetes mellitus and its anti-lipogenesis effects in the liver, as studied in mice models; while few clinical trials have evaluated its effect on liver fat content and liver function. This study aimed to evaluate the effect of empagliflozin on the treatment of non‐alcoholic fatty liver disease in type 2 diabetes mellitus patients. Scopus, Cochran Library, PubMed, and Web of Science databases were searched from 1990 to 2022 with reference checking and citation searching to identify additional studies. The inclusion criteria for studies included were the evaluation of patients with non‐alcoholic fatty liver disease and type 2 diabetes being treated with empagliflozin for 24 weeks. Our interest outcomes were Liver fat, Alanine transaminase (ALT), and Aspartate transaminase (AST). Data analysis random effect size model was used for pooling data to calculate mean differences in RevMan Version 5.3. I<sup>2</sup> was used to evaluate heterogeneity. Three clinical trial studies were included with 2344 patients. In pooled ALT mean difference evaluation within 24 weeks of studies, there was a significant difference between subjects receiving empagliflozin versus controls (MD = -6.6 CI95% (-10.27 to -3.73; P = 0.06; I<sup>2</sup> = 99%). In the case of AST (MD = -9.06 CI95% (-20.45 to 2.34; P = 0.12; I<sup>2</sup> = 98%) and Liver fat (MD = -4.46 CI95% (-10.06 to 0.77; P = 0.09; I<sup>2</sup> = 98%), there was not any significant difference between subjects receiving empagliflozin versus controls. While empagliflozin seems to be effective in lowering ALT levels; further studies are needed to confirm its efficacy in lowering liver fat.</p></div>
2023-09-29T00:00:00-04:00
Copyright (c) 2023 © The Author(s)